

# **What Urologists Want To Know: Addressing Current Questions and Controversies in the Management of Prostate Cancer**

*A Virtual CME Satellite Symposium During the  
American Urological Association (AUA) 2021 Annual Meeting*

**Monday, September 13, 2021**

**5:00 PM – 6:30 PM ET**

## **Faculty**

**Leonard G Gomella, MD**

**Maha Hussain, MD, FACP, FASCO**

**A Oliver Sartor, MD**

**Neal D Shore, MD**

## **Moderator**

**Neil Love, MD**

# Faculty



**Leonard G Gomella, MD**

The Bernard W Godwin Professor of Prostate Cancer  
Chairman, Department of Urology  
Senior Director, Clinical Affairs, Sidney Kimmel Cancer Center  
Enterprise VP for Urology, Jefferson Health System  
Thomas Jefferson University and Hospital  
Philadelphia, Pennsylvania



**Neal D Shore, MD**

Director, CPI, Carolina Urologic Research Center  
Chief Medical Officer, Surgery/Urology  
GenesisCare, US  
Medical Director, CUSP: Clinical Research  
Consortium  
Myrtle Beach, South Carolina



**Maha Hussain, MD, FACP, FASCO**

Genevieve Teuton Professor of Medicine  
Division of Hematology/Oncology  
Deputy Director  
Robert H Lurie Comprehensive Cancer Center  
Northwestern University Feinberg School of Medicine  
Chicago, Illinois



**Moderator**

**Neil Love, MD**

Research To Practice  
Miami, Florida



**A Oliver Sartor, MD**

Laborde Professor for Cancer Research  
Medical Director, Tulane Cancer Center  
Assistant Dean for Oncology  
Tulane Medical School  
New Orleans, Louisiana

## Commercial Support

This activity is supported by educational grants from Merck and Sanofi Genzyme.

## Dr Love — Disclosures

**Dr Love** is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

# Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

# Dr Gomella — Disclosures

<b>Advisory Committee</b>	AstraZeneca Pharmaceuticals LP
---------------------------	--------------------------------

## Dr Hussain — Disclosures

<b>Advisory Committee and Consulting Agreements</b>	AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Pfizer Inc
<b>Honoraria</b>	Astellas, AstraZeneca Pharmaceuticals LP, Phillips Gilmore Oncology Communications Inc, Precisca, Sanofi Genzyme, UroToday
<b>Patents, Royalties, Other Intellectual Property</b>	Systems and Methods for Tissue Imaging, 3676, Licensed to IMBIO

## Dr Sartor — Disclosures


<b>Consulting Agreements</b>	Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien München AG, Janssen Biotech Inc, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals, TeneoBio, Theragnostics
<b>Contracted Research</b>	Advanced Accelerator Applications, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Endocyte Inc, Invitae, Janssen Biotech Inc, Lantheus, Merck, Progenics Pharmaceuticals Inc, TeneoBio
<b>Data and Safety Monitoring Board/Committee</b>	AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pfizer Inc, Myovant Sciences



## Dr Shore — Disclosures

<b>Consulting Agreements</b>	AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, CG Oncology, Clovis Oncology, Dendreon Pharmaceuticals Inc, Exact Imaging, Exact Sciences Inc, FerGene, Foundation Medicine, GenesisCare, Invitae, Janssen Biotech Inc, MDxHealth, Merck, Myovant Sciences, Myriad Genetic Laboratories Inc, NymoxPharmaceutical Corporation, Pacific Edge, Pfizer Inc, Phosphorus, Propella Therapeutics Inc, Sanofi Genzyme, Sesen Bio, Tolmar, UroGen Pharma
<b>Speakers Bureau</b>	Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Foundation Medicine, Guardant Health, Janssen Biotech Inc, Merck, Pfizer Inc

# We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.

# Familiarizing Yourself with the Zoom Interface

## Expand chat submission box

The screenshot displays a Zoom meeting interface. At the top, a video bar shows participants: RTP Coordinat..., Kirsten Miller, RTP Mike Rivera, and Lisa Suarez. Below the video bar, a 'Recording...' indicator is visible. The main content area shows a presentation slide titled 'Meet The Professor Program Steering Committee'. The slide lists six members of the steering committee, each with a portrait photo and their name and affiliation:


- John N Allan, MD**  
Assistant Professor of Medicine  
Weill Cornell Medicine  
New York, New York
- Ian W Flinn, MD, PhD**  
Director of Lymphoma Research Program  
Sarah Cannon Research Institute  
Tennessee Oncology  
Nashville, Tennessee
- Steven Coutre, MD**  
Professor of Medicine (Hematology)  
Stanford University School of Medicine  
Stanford, California
- Prof John G Gribben, MD, DSc, FMedSci**  
Chair of Medical Oncology  
Barts Cancer Institute  
Queen Mary University of London  
Charterhouse Square  
London, United Kingdom
- Matthew S Davids, MD, MMSc**  
Associate Professor of Medicine  
Harvard Medical School  
Director of Clinical Research  
Division of Lymphoma  
Dana-Farber Cancer Institute  
Boston, Massachusetts
- Brian T Hill, MD, PhD**  
Director, Lymphoid Malignancy Program  
Cleveland Clinic Taussig Cancer Institute  
Cleveland, Ohio

The chat window on the right is titled 'Chat' and shows two messages from 'Me to Panelists' and 'Me to Panelists and Attendees' at 4:31 PM and 4:32 PM respectively. Each message says: 'Welcome and thank you for attending! To access the slides from today's session please use the link below. [http://images.researchtopractice.com/2021/Meetings/Slides/MTP\\_ToGo\\_CLL\\_2021\\_April1.pdf](http://images.researchtopractice.com/2021/Meetings/Slides/MTP_ToGo_CLL_2021_April1.pdf)'. At the bottom of the chat window, there is a 'To:' dropdown menu set to 'Panelists and Attendees' and a text input field labeled 'Type message here...'. A large red arrow points to this input field.

Drag the white line above the submission box up to create more space for your message.

# Familiarizing Yourself with the Zoom Interface

## Increase chat font size



**Press Command (for Mac) or Control (for PC) and the + symbol.  
You may do this as many times as you need for readability.**

# ONCOLOGY TODAY

WITH DR NEIL LOVE

## Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting



DR ARJUN BALAR  
NYU PERLMUTTER CANCER CENTER




Listen on  
**Apple Podcasts**



**Spotify**



Listen on  
**Google Podcasts**





# ***Meet The Professor***

## **Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma**

**Tuesday, September 14, 2021**

**5:00 PM – 6:00 PM ET**

### **Faculty**

**Neeraj Agarwal, MD**

### **Moderator**

**Neil Love, MD**

# ***Meet The Professor***

## **Optimizing the Clinical Management of Hodgkin and Non-Hodgkin Lymphomas**

**Thursday, September 16, 2021  
5:00 PM – 6:00 PM ET**

**Faculty**

**Loretta J Nastoupil, MD**

**Moderator**

**Neil Love, MD**

# ***Meet The Professor***

## **Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers**

**Friday, September 17, 2021  
12:00 PM – 1:00 PM ET**

**Faculty**

**Philip A Philip, MD, PhD, FRCP**

**Moderator**

**Neil Love, MD**



# ***Meet The Professor***

## **Optimizing the Selection and Sequencing of Therapy for Patients with HER2-Positive Breast Cancer**

**Wednesday, September 22, 2021  
5:00 PM – 6:00 PM ET**

### **Faculty**

**Sara M Tolaney, MD, MPH**

### **Moderator**

**Neil Love, MD**

# ***Meet The Professor***

## **Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers**

**Monday, September 27, 2021  
5:00 PM – 6:00 PM ET**

**Faculty**

**Zev Wainberg, MD, MSc**

**Moderator**

**Neil Love, MD**

***Meet The Professor***  
**Optimizing the Selection and Sequencing  
of Therapy for Patients with  
Triple-Negative Breast Cancer**

**Tuesday, September 28, 2021  
5:00 PM – 6:00 PM ET**

**Faculty**

**Professor Peter Schmid, MD, PhD**

**Moderator**

**Neil Love, MD**

***Thank you for joining us!***

***CME credit information will be emailed to each participant within 3 business days.***





... syndrome) and multiple recurrent  
... inhibitor vismodegib, also  
... prostatectomy/bilateral pelvic lymph  
... (b7) Stage IIIb prostate  
... Not a candidate for RT, hence  
... ed on enzalutamide, continuing  
... whether to add in another hormone in  
... balance doubling time, time since

**Case 2: 57-year-old**

- History of PTCH1-1 deficiency (Gorlin, Marfan syndrome) and multiple recurrent basal cell cancers; currently on hedgehog inhibitor vismodegib; also asymptomatic myeloma
- 2016: PSA 15, core needle biopsy, radical prostatectomy/bilateral pelvic lymph node dissection + Gleason 4 + 3 = 7 pT3a/b (b7) Stage IIIb prostate adenocarcinoma
- Postop PSA rose within 6 months of surgery. Not a candidate for RT, hence treated with GnRH. Failure 1 year later; started on enzalutamide, continuing GnRH. Current PSA undetectable.

**Questions for the faculty:**  
In a more typical situation, how do you decide whether to add in another hormone in a patient on ADT with a rising PSA? How do you balance doubling time, time since original surgery, time on ADT and PSA level?  
How do you choose which antiandrogen?































































A 65-year-old man s/p radical prostatectomy follows  
PSA-only recurrence (M0) receives an LHRH agonist  
to a PSA level of 14 ng/dL with a doubling time of 3  
imaging are negative. The patient has asked you to  
diagnosed with metastatic disease in 3 years if he c  
alone. How would you respond?

- Less than 5%
- 5%-10%
- 11%-25%
- 26%-35%
- 36%-70%
- Greater than 70%











































































